Symbicort Turbuhaler 30/60 Clinical Experience Investigation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01232348

Acronym

SURE

Enrollment

3643

Registered

2010-11-02

Start date

2010-01-31

Completion date

2011-10-31

Last updated

2011-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial Asthma

Keywords

bronchial asthma, Symbicort

Brief summary

The purpose of this study is to confirm the safety (ADR related to beta stimulant drugs, unexpected ADRs) and efficacy of Symbicort in daily practice and the control status on bronchial asthma and Patient satisfaction

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients treated with Symbicort for the first time due to bronchial asthma

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Incidence of Adverse Events	Range of 12 weeks

Secondary

Measure	Time frame
The level of asthma control	Range of 12 weeks
The level of patient satisfaction with Symbicort	Range of 12 weeks

Countries

Japan

Outcome results